OBSERVATIONAL STUDY on VIRAL SHEDDING and IMMUNOLOGICAL RESPONSE of OROPOUCHE VIRUS
Launched by IRCCS SACRO CUORE DON CALABRIA DI NEGRAR · Mar 18, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the body responds to the Oropouche Virus (OROV) and how long the virus can be found in the body after someone is infected. The researchers will look at blood and other samples from participants to better understand the immune response and the duration of the virus in the body. This study is currently recruiting participants aged 18 and older who have tested positive for the virus.
To participate, individuals need to agree to take part in the study and allow their leftover samples to be used for research. It's important that participants provide informed consent, which means they understand what the study involves and agree to it. If you join the study, you can expect to provide samples during the study period, and your participation will help improve understanding of Oropouche Virus infections.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients resulted positive to the RT-PCR for OROV;
- • informed consent to the participation to the study and to personal data's treatment and/or donation of residual samples to Tropika Biobank;
- • patients ≥ 18 years old.
- • Exclusion Criteria
- • • lack of signed informed consent.
About Irccs Sacro Cuore Don Calabria Di Negrar
IRCCS Sacro Cuore Don Calabria di Negrar is a leading research institute dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. Located in Negrar, Italy, this renowned institution specializes in a range of therapeutic areas, focusing on translational research that bridges laboratory findings with clinical applications. With a commitment to excellence in patient safety and ethical standards, IRCCS Sacro Cuore Don Calabria collaborates with a network of healthcare professionals, researchers, and academic institutions to facilitate groundbreaking studies aimed at enhancing treatment options and outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Negrar Di Valpolicella, Vr, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported